Tenaya Therapeutics (TNYA) News Today $1.41 -1.47 (-51.04%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Positive Buy Recommendation for Tenaya Therapeutics Based on Promising TN-201 Gene Therapy ResultsDecember 17 at 5:50 PM | markets.businessinsider.comTenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201December 17 at 5:50 PM | markets.businessinsider.comTenaya in selloff after early-stage data for gene therapyDecember 17 at 5:50 PM | msn.comTenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024December 16 at 4:30 PM | globenewswire.comJacobs Levy Equity Management Inc. Purchases 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Jacobs Levy Equity Management Inc. boosted its position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 204.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 337,265 shares of the company's stock after buDecember 10, 2024 | marketbeat.comRA Capital Management L.P. Sells 639,760 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)RA Capital Management L.P. trimmed its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,982,587 shares of the company's stockDecember 5, 2024 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest UpdateTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 13,120,000 shares, a growth of 150.4% from the October 31st total of 5,240,000 shares. Based on an average daily volume of 2,310,000 shares, the short-interest ratio is currently 5.7 days. Currently, 20.0% of the shares of the company are sold short.November 28, 2024 | marketbeat.comPositive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy RatingNovember 26, 2024 | markets.businessinsider.comPositive Outlook for Tenaya Therapeutics Amidst Strategic Advancements in PKP2-ARVC Gene TherapyNovember 26, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from BrokeragesShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objectiveNovember 24, 2024 | marketbeat.comTenaya Therapeutics Reports Q3 2024 Progress and Financial ResultsNovember 22, 2024 | markets.businessinsider.comTenaya Therapeutics reports inducement grants under Nasdaq listing ruleNovember 20, 2024 | markets.businessinsider.comTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)November 19, 2024 | finance.yahoo.comHC Wainwright Has Bullish Forecast for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per shareNovember 11, 2024 | marketbeat.comLeerink Partnrs Has Bullish Outlook for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for Tenaya Therapeutics in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1November 11, 2024 | marketbeat.comWhat is Lifesci Capital's Forecast for TNYA FY2024 Earnings?Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Stock analysts at Lifesci Capital upped their FY2024 earnings estimates for shares of Tenaya Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Lifesci Capital analyst C. Jubinville now forecasts thNovember 11, 2024 | marketbeat.comEquities Analysts Set Expectations for TNYA FY2024 EarningsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities research analysts at William Blair boosted their FY2024 EPS estimates for shares of Tenaya Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst S. Corwin now forecasts that the companNovember 11, 2024 | marketbeat.comTenaya Therapeutics price target raised to $18 from $16 at CanaccordNovember 10, 2024 | markets.businessinsider.comPromising Developments and Strong Financials Drive Buy Rating for Tenaya TherapeuticsNovember 8, 2024 | markets.businessinsider.comPositive Outlook for Tenaya Therapeutics: Strong Clinical Progress and Financial Position Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tenaya Therapeutics Amid Positive DSMB Update and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan CapitalChardan Capital cut their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.November 7, 2024 | marketbeat.comTenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.com550,700 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by abrdn plcabrdn plc acquired a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 550,700 shares of the company's stock, valued at approximately $1,063,000. abrdn plc owned 0.70% of Tenaya TheNovember 5, 2024 | marketbeat.comHere's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn SituationNovember 2, 2024 | uk.finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month target price among bOctober 30, 2024 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)October 22, 2024 | markets.businessinsider.comOptimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201October 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Sana Biotechnology (SANA)October 19, 2024 | markets.businessinsider.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMOctober 18, 2024 | finanznachrichten.dePromising Developments and DSMB Approval Drive Buy Rating for Tenaya TherapeuticsOctober 18, 2024 | markets.businessinsider.comTenaya Therapeutics (TNYA) Receives a Buy from Piper SandlerOctober 18, 2024 | markets.businessinsider.comTenaya Therapeutics (NASDAQ:TNYA) Rating Reiterated by Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comTenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMOctober 17, 2024 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTenaya Therapeutics (NASDAQ:TNYA) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by BrokeragesShares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have received a consensus rating of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objectiveOctober 5, 2024 | marketbeat.comOptimistic Buy Rating for Tenaya Therapeutics as Clinical Milestone Nears in Gene Therapy for CardiomyopathyOctober 2, 2024 | markets.businessinsider.comBuy Rating Reiterated on Tenaya Therapeutics Amid Promising Gene Therapy Prospects for HCMSeptember 24, 2024 | markets.businessinsider.comOwning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA),September 21, 2024 | finance.yahoo.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from AnalystsTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target priceSeptember 10, 2024 | marketbeat.comTenaya Therapeutics to Participate in Upcoming Investment ConferencesSeptember 3, 2024 | globenewswire.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Insider Whittemore Tingley Sells 7,428 SharesAugust 17, 2024 | insidertrades.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Buy" from BrokeragesTenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year targAugust 16, 2024 | marketbeat.comVanguard Group Inc. Increases Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Vanguard Group Inc. boosted its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 16.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,862,916 shares of the company's stock afteAugust 13, 2024 | marketbeat.comBuy Rating on Tenaya Therapeutics: Promising Clinical Trials and Solid Financial PositionAugust 10, 2024 | markets.businessinsider.comTNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comPrice T Rowe Associates Inc. MD Sells 1,198,021 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)Price T Rowe Associates Inc. MD reduced its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) by 26.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,346,522 shares of the cAugust 3, 2024 | marketbeat.com5 Penny Stocks With 250% Upside in 1 Year According to Wall StreetJuly 30, 2024 | 247wallst.comAnalysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)July 26, 2024 | markets.businessinsider.com Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now TNYA Media Mentions By Week TNYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNYA News Sentiment▼0.740.79▲Average Medical News Sentiment TNYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNYA Articles This Week▼42▲TNYA Articles Average Week Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ArriVent BioPharma News Today Immatics News Today Replimune Group News Today uniQure News Today 89bio News Today Pliant Therapeutics News Today Relay Therapeutics News Today Anavex Life Sciences News Today Immunome News Today Kura Oncology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TNYA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
